Silo Pharma Inc. (NASDAQ: SILO) has authorized a share repurchase program to acquire up to $1 million of the company's common stock, according to a company announcement. The biopharmaceutical and cryptocurrency treasury company's board of directors approved the program, which allows purchases on the open market, through privately negotiated transactions, or otherwise, in compliance with Securities and Exchange Commission rules and applicable legal requirements.
The timing and amount of any repurchases will depend on market conditions and corporate and regulatory limitations. The program does not obligate the company to acquire a specific number of shares and may be suspended or discontinued at its discretion. According to the company's quarterly report for the period ended Sept. 30, 2025, Silo Pharma reported 13,318,273 shares of common stock outstanding as of Nov. 13, 2025.
This announcement is significant because share repurchase programs typically signal management's confidence in the company's long-term value and financial health. For investors, such programs can potentially increase earnings per share and shareholder value by reducing the number of outstanding shares. The move comes as Silo Pharma continues to develop its therapeutic portfolio focused on underserved conditions including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases.
The company's pipeline includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. Silo's research is conducted in collaboration with leading universities and laboratories, positioning the company at the intersection of pharmaceutical development and emerging financial technologies through its cryptocurrency treasury operations.
For those following the company's developments, the latest news and updates relating to SILO are available in the company's newsroom at https://ibn.fm/SILO. The full press release detailing the share repurchase authorization can be viewed at https://ibn.fm/gU3uZ.
The announcement was distributed through MissionIR, a specialized communications platform that assists IR firms with syndicated content to enhance the visibility of companies within the investment community. MissionIR is one of 75+ brands within the Dynamic Brand Portfolio at IBN that delivers access to wire solutions, article syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. More information about MissionIR is available at https://www.MissionIR.com.
